NASDAQ:BIOL - BIOLASE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.05
  • Forecasted Upside: 259.02 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.57
▼ -0.02 (-3.38%)

This chart shows the closing price for BIOL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BIOLASE Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOL

Analyst Price Target is $2.05
▲ +259.02% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BIOLASE in the last 3 months. The average price target is $2.05, with a high forecast of $3.00 and a low forecast of $1.15. The average price target represents a 259.02% upside from the last price of $0.57.

This chart shows the closing price for BIOL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in BIOLASE.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/19/2021Ascendiant Capital MarketsBoost Price TargetPositive ➝ Buy$2.00 ➝ $3.00Low
5/14/2021Maxim GroupReiterated RatingBuy$2.00Low
3/26/2021Maxim GroupReiterated RatingBuy$2.00Low
3/8/2021Colliers SecuritiesReiterated RatingBuy$1.15High
1/26/2021Maxim GroupBoost Price TargetBuy$1.00 ➝ $2.00High
10/14/2020Maxim GroupInitiated CoverageBuy$1.00Low
8/12/2019Ascendiant Capital MarketsSet Price TargetBuy$3.00High
6/19/2019BenchmarkInitiated CoverageSpeculative Buy ➝ Speculative Buy$2.00High
4/30/2019Dougherty & CoReiterated RatingBuyHigh
3/7/2019Singular ResearchReiterated RatingBuyHigh
4/25/2017Singular ResearchInitiated CoverageBuy$12.50Low
(Data available from 10/23/2016 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/24/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021
  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2021

Current Sentiment

  • 1 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
BIOLASE logo
BIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems uses a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.
Read More

Today's Range

Now: $0.57
Low: $0.57
High: $0.60

50 Day Range

MA: $0.67
Low: $0.58
High: $0.79

52 Week Range

Now: $0.57
Low: $0.26
High: $1.51

Volume

1,963,885 shs

Average Volume

12,233,087 shs

Market Capitalization

$86.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56

Frequently Asked Questions

What sell-side analysts currently cover shares of BIOLASE?

The following equities research analysts have issued stock ratings on BIOLASE in the last twelve months: Ascendiant Capital Markets, Colliers Securities, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for BIOL.

What is the current price target for BIOLASE?

3 Wall Street analysts have set twelve-month price targets for BIOLASE in the last year. Their average twelve-month price target is $2.05, suggesting a possible upside of 257.9%. Ascendiant Capital Markets has the highest price target set, predicting BIOL will reach $3.00 in the next twelve months. Colliers Securities has the lowest price target set, forecasting a price of $1.15 for BIOLASE in the next year.
View the latest price targets for BIOL.

What is the current consensus analyst rating for BIOLASE?

BIOLASE currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIOL will outperform the market and that investors should add to their positions of BIOLASE.
View the latest ratings for BIOL.

What other companies compete with BIOLASE?

How do I contact BIOLASE's investor relations team?

BIOLASE's physical mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company's listed phone number is (949) 361-1200 and its investor relations email address is [email protected] The official website for BIOLASE is www.biolase.com.